- 全部删除
- 您的购物车当前为空
HSD17B13-IN-27 (compound 30) 作为hydroxysteroid 17?-dehydrogenase 13 (HSD17B13) 的高效抑制剂,其针对雌二醇和白三烯 B3 的IC50值分别为小于 0.1 μM 和小于 1 μM。该化合物在非酒精性脂肪肝疾病 (NAFLD) 及其子类非酒精性脂肪性肝炎 (NASH) 的研究中显示出显著的应用潜力。
HSD17B13-IN-27 (compound 30) 作为hydroxysteroid 17?-dehydrogenase 13 (HSD17B13) 的高效抑制剂,其针对雌二醇和白三烯 B3 的IC50值分别为小于 0.1 μM 和小于 1 μM。该化合物在非酒精性脂肪肝疾病 (NAFLD) 及其子类非酒精性脂肪性肝炎 (NASH) 的研究中显示出显著的应用潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 待询 | 10-14周 | |
50 mg | 待询 | 10-14周 |
HSD17B13-IN-27 相关产品
产品描述 | HSD17B13-IN-27 (compound 30) serves as a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 µM and approximately less than 1 µM for estradiol and Leukotriene B3, respectively, as substrates. This compound is crucial in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1]. |
分子量 | 414.45 |
分子式 | C21H19FN2O4S |
CAS No. | 2758802-31-0 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容